Safety of long-term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review

Clinical Infectious Diseases

Volumn 28, Issue 2, 1999, Pages 299-308

  Segev, S ^a,b   Yaniv, I ^a,b   Haverstock, D ^a,b   Reinhart, H ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ARTICLE; BACTERIAL INFECTION; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOMYELITIS; PRIORITY JOURNAL; REACTIVE ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION; SOFT TISSUE INFECTION; TREATMENT OUTCOME; VERTIGO;

EID: 0033010008     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515132     Document Type: Article

References (55)

1. 1. Schacht P. Clinical use of quinolones. In: Kuhlmann J, Dalhoff A, Zeiler H, eds. Quinolone antibacterials. Berlin: Springer-Verlag, 1998:421-53.
2. 2. Hooper DC, Wolfson JS. Adverse events. In: Hooper DC, Wolfson JS, eds. Quinolone antimicrobial agents. Washington, DC: American Society for Microbiology, 1993:489-512.
3. 3. Fink M, Snydman D, Niederman M. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38:547-57.
4. 4. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997;25:1327-33.
5. 5. Solomkin J, Dellinger P, Reinhart H. Results of randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surgery 1996;223:303-15.
6. 6. Kuhlmann J, Schaeffer H, Beermann D. Clinical pharmacology: adverse reactions of fluoroquinolones. In: Kuhlmann J, Dalhoff A, Zeiler H, eds. Quinolone antibacterials. Berlin: Springer-Verlag, 1998:378-403.
7. 7. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present and future. Drug Saf 1995;13:343-58.
8. 8. Wolfson J. Quinolone antimicrobial agents: adverse effects and bacterial resistance. Eur J Clin Microbiol Infect Dis 1989;8:1080-92.
9. 9. Paton J, Reeves D. Adverse reactions to the fluoroquinolones. Adverse Drug Reaction Bulletin 1992;153:575-8.
10. 10. Norrby S, Lietman P. Safety and tolerability of fluoroquinolones. Drugs 1993;45(suppl 3):59-64.
11. 11. Ferguson J, Johnson B. Clinical and laboratory studies of the photosensitizing potential of norfloxacin, a 4-quinolone broad-spectrum antibiotic. Br J Dermatol 1993;128:285-95.
12. 12. von Keutz E, Christ W. Toxicology and safety pharmacology of quinolones. In: Kuhlmann J, Dalhoff A, Zeiler H, eds. Quinolone antibacterials. Berlin: Springer-Verlag, 1998:297-337.
13. 13. Paton J, Reeves D. Clinical features and management of adverse effects of quinolone antibacterials. Drug Saf 1991;6:8-27.
14. 14. Lietman P. Fluoroquinolone toxicities. An update. Drugs 1995;49(suppl 2):159-63.
15. 15. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994;18:946-50.
16. 16. Royer R, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones. Therapie 1994;49:75-6.
17. 17. Zaudig M, von Bose M, Weber M. Psychotic effects of ofloxacin. Pharmacopsychiatry 1989;22:11-5.
18. 18. Iida M, Yasuba M, Nakajima F. Four week oral subacute toxicity study of sparfloxacin in beagle dogs. Chemotherapy (Tokyo) 1991;39(suppl 4):195-202.
19. 19. Domagala J. Structure-activity and structure-side effect relationship for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685-708.
20. 20. Iravani A. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. Am J Med 1992;92(suppl 4A):75S-81S.
21. 21. Forster C, Kociok K, Shakibaei M. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996;70:474-81.
22. 22. Mitsui Y. Pharmacological characteristics of fluoroquinolones. J Eye 1992;9:215-23.
23. 23. Nomura M, Yamada M, Yamamura II. Ophthalmotoxicity and ototoxicity of the new quinolone antibacterial agent levofloxacin in Long Evans rats. Arzneimittelforschung 1992;43:398-403.
24. 24. Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med 1989;87(suppl 5A):37S-9S.
25. 25. Burdge DR, Nakielna EM, Rabin HR. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1995;39:793.
26. 26. Neringer R, Forsgren A, Hansson C. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infection: three-day versus seven-day treatment. Scand J Infect Dis 1992;24:773-80.
27. 27. Sheehan GJ, Harding GK, Haase DA. Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of placebo in the therapy of complicated urinary tract infection. Antimicrob Agents Chemother 1988;32:1292-3.
28. 28. Schacht P, Arcieri G, Branolte J. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection 1988;16(suppl 1):S29-43.
29. 29. Davis R, Markham H, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996;51:1019-74.
30. 30. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am 1995;9:715-30.
31. 31. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy 1993;13(2 part 2):4S-17S.
32. 32. Wolfson J, Hooper DC. Overview of fluoroquinolone safety. Am J Med 1991;91(suppl 6A):153S-61S.
33. 33. Schacht P, Arcieri G, Hullmann R. Safety of oral ciprofloxacin. An update based on clinical trial results. Am J Med 1989;87(suppl 5A):98S-102S.
34. 34. Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med 1987;82:266-9.
35. 35. Snydman DR, Barza M, McGowan K, et al. Randomized comparative trial of ciprofloxacin for treatment of patients with osteomyelitis. Rev Infect Dis 1989;11(suppl 5):S39-40.
36. 36. Valtonen VV, Karppinen L, Kariniemi A. A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods. Scand J Infect Dis Suppl 1989;60:79-83.
37. 37. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990;34:40-3.
38. 38. Mader J, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg Am 1990;72:104-10.
39. 39. Trujillo I, Valladares G, Nava A. Ciprofloxacin in the treatment of chronic osteomyelitis in adults. Drugs 1993;45(suppl 3):454-5.
40. 40. Gentry LO, Rodriguez-Gomez G, Roniker B, et al. The safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of acute and chronic osteomyelitis [abstract no 121]. In: Selected abstracts of the 5th International Symposium on the New Quinolones (Singapore). 1994.
41. 41. Huovinen S, Kotilainen P, Jarvinen H. Comparison of ciprofloxacin or trimethoprim therapy for venous leg ulcers: results of a pilot study. J Am Acad Dermatol 1994;31(2 part 1):279-81.
42. 42. Jacobson MA, Yajko D, Northfelt D, et al. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 1993;168:112-9.
43. 43. Kennedy N, Fox R, Uiso L, et al. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 1993;32:897-902.
44. 44. Mohanty K, Dhangaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993;104:1194-8.
45. 45. Toivanen A, Yli-Kerttula T, Luukkainen R, et al. Effect of antimicrobial treatment on chronic reactive arthritis. Clin Exp Rheumatol 1993;11: 301-7.
46. 46. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease. A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91: 328-32.
47. 47. Turunen U, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998 (in press).
48. 48. Turunen U. Ciprofloxacin treatment combined with conventional therapy in Crohn's disease. A prospective, double blind, placebo-controlled study. Data of file, Bayer AG, Wuppertal. 1997.
49. 49. Chaowagul W, Suputtamongkul Y, Smith MD, et al. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1997;91:599-601.
50. 50. Hibberd PL, Tolkoff-Rubin NE, Doran M, et al. Trimethoprim sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. Online J Curr Clin Trials [serial online] 1992;doc.15.
51. 51. Kumazawa J, Matsumoto T, Tanaka M, et al. Suppression of recurrence of complicated UTI by low dose ciprofloxacin. Drugs 1993;45(suppl 3):340.
52. 52. Biering-Sorensen F, Hoiby N, Nordenbo A, et al. Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, crossover, placebo-controlled study in patients with spinal cord lesion. J Urol 1994;151:105-8.
53. 53. Watanabe A, Motomiya M, Nukiwa T, et al. A well-controlled comparative clinical study of the combination regimen of ciprofloxacin plus erythromycin for the treatment of repeated acute exacerbations of chronic respiratory tract infections. Chemotherapy (Tokyo) 1994;42: 1194-201.
54. 54. Krcmery S, Hromec J. Long-term chemoprophylaxis of recurrent urinary tract infections (UTI) in women: pefloxacin vs ciprofloxacin. In: Proceedings of the 10th Mediterranean Congress on Chemotherapy (Antalya, Turkey). Bologna, Italy: Monduzzi Editore, 1996:201-4.
55. 55. Moyses-Neto M, Costa RS, Reis MA, et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin Transpl 1997;11(5 part 1):446-52.